(Q47356366)

14 January 2018

title

Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles (English)

1 reference

14 January 2018

1 reference

Zhengrong Cui

1

1 reference

14 January 2018

Jigna Patel

2

1 reference

14 January 2018

Marina Tuzova

3

1 reference

14 January 2018

Phillip Ray

4

1 reference

14 January 2018

Ryan Phillips

5

1 reference

14 January 2018

Jerold G Woodward

6

1 reference

14 January 2018

Avindra Nath

7

1 reference

14 January 2018

Russell J Mumper

8

1 reference

14 January 2018

language of work or name

English

0 references

publication date

1 June 2004

1 reference

14 January 2018

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 January 2018

volume

22

1 reference

14 January 2018

issue

20

1 reference

14 January 2018

page(s)

2631-2640

1 reference

14 January 2018

HIV-1 Tat: coping with negative elongation factors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Structural studies of HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Control of RNA initiation and elongation at the HIV-1 promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Cellular uptake of the tat protein from human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Tat protein induces self-perpetuating permissivity for productive HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Role of Na+/H+ exchangers, excitatory amino acid receptors and voltage-operated Ca2+ channels in human immunodeficiency virus type 1 gp120-mediated increases in intracellular Ca2+ in human neurons and astrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Tat-mediated delivery of heterologous proteins into cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Decreased ability of HIV-1 tat protein-treated accessory cells to organize cellular clusters is associated with partial activation of T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Coating of cationized protein on engineered nanoparticles results in enhanced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Genetic immunization using nanoparticles engineered from microemulsion precursors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Topical immunization using nanoengineered genetic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Metabolism of synthetic surfactants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Immunological concepts of vaccine adjuvant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.013

10.1016/J.VACCINE.2003.12.013

7 January 2021

Identifiers

DOI

1 reference

14 January 2018

1 reference

14 January 2018